EXAGEN INC.(XGN)Stock Analysis

XGN Stock Analysis & AI Quality Score

AI stock analysis and institutional research for EXAGEN INC. (XGN), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores XGN at 25.2/100 on a 32-signal composite quality model, placing it at rank #2,554 of 2,879 stocks — the bottom half of the AI-ranked universe. Areas of concern include balance sheet strength (6.6) and institutional flow (8.3), which score below median versus the broader universe. Shareholder dilution risk is elevated at 32.1/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), EXAGEN INC. reports quarterly revenue of $17.3M, net income of $-4.0M, an operating margin of -19.7%. Top institutional holders of XGN by reported 13-F value include BALYASNY ASSET MANAGEMENT L.P., WEXFORD CAPITAL, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. XGN trades on the Nasdaq exchange and files with the SEC under CIK 1274737. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate XGN daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for EXAGEN INC. directly from SEC EDGAR. EXAGEN INC.'s 13F Pro composite quality score has ranged between 14 and 29 since 2021, currently 25.2 — an improving long-term trajectory across 30 quarterly and live scoring snapshots.